恶性肿瘤合并糖尿病患者化疗应用糖皮质激素的安全性分析

Analysis of the Safety of Glucocorticoids in Patients with Malignant Tumor and Diabetes Mellitus

目的研究并分析恶性肿瘤合并糖尿病患者化疗应用糖皮质激素的安全性。方法选取该院在2014年3月—2017年3月期间收治的36例恶性肿瘤合并糖尿病患者。按照随机数字表法将其分为两组,各18例。参照组患者在化疗期间未使用糖皮质激素,实验组患者在化疗期间使用糖皮质激素。对比两组患者的临床效果。结果参照组患者的治疗效果明显低于实验组,组间差异有统计学意义(P<0.05)。实验组患者的不良反应发生情况相比于参照组,组间差异有统计学意义(P<0.05)。结论对恶性肿瘤合并糖尿病患者在化疗期间使用糖皮质激素,在治疗期间需对患者的血糖进行控制,具有一定的安全性,值得临床上借鉴以及进一步普及。

Objective This paper tries to study and analyze the safety of glucocorticoids in patients with malignant tumor and diabetes mellitus. Methods 36 cases of malignant tumor with diabetes mellitus treated in this hospital from March 2014 to March 2017 were selected and divided into two groups according to the random number table method, with 18 cases in each group. The patients in the control group did not use glucocorticoids during chemotherapy, and the patients in the experimental group used glucocorticoids during chemotherapy. The clinical effects of the two groups were compared. Results The therapeutic effect of the control group was significantly lower than that in the experimental group, and the difference between groups was significant（P〈0.05）. The adverse reactions of patients in the experimental group were significantly different from those in the control group （P〈0.05）. Conclusion The application of glucocorticoids in patients with malignant tumor and diabetes mellitus can control the blood glucose of the patients during the period of chemotherapy with certain security, which is worth of reference and further clinical popularization.